Журнал дерматологии и дерматологических заболеваний

Atopic dermatitis (AD) is a type of inflammation of the skin. It results in itchy, swollen, red, and cracked skin. Mesenchymal Stem Cells (MSCs) could suppress allergic responses in AD. Indeed, the immunomodulatory ability of MSCs can be usefully applied for the treatment of autoimmune and inflammation – related diseases such as asthma, rhinitis and dermatitis. We aims to evaluate safety and efficacy in DNFB – induced atopic dermatitis mouse model after a subcutaneous infusion of xenogeneic human Adipose Tissue – derived MSCs (hAT-MSCs). Therefore, hAT-MSCs have possibility as a new drug for AD.

Atopic dermatitis (AD) is a major inflammatory skin disease. Most patients with atopic dermatitis have elevated serum levels of mast cells and IgE. Mesenchymal stem cell (MSC) has been applied for the therapy of allergic disorders due to its beneficial immunomodulatory abilities. We sought to investigate the safety and the efficacy of human adipose tissue-derived MSCs (hAT-MSCs) in mouse atopic dermatitis (AD) model and to determine the serum levels of mast cells (MC) and IgE after subcutaneous administration